Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 20/20 | 0.60 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15419995 | 0.92 | HSD11B1 (0.70) | HSD11B1KCNH2 | |
| SCHEMBL15419813 | 0.92 | HSD11B1 (0.71) | HSD11B1HSD11B2 | |
| SCHEMBL15419503 | 0.91 | HSD11B1 (0.73) | HSD11B1KCNH2 | |
| SCHEMBL15419897 | 0.90 | HSD11B1 (0.56) | HSD11B1KCNH2 | |
| SCHEMBL15419602 | 0.89 | HSD11B1 (0.54) | HSD11B1 | |
| SCHEMBL15419635 | 0.86 | HSD11B1 (0.65) | HSD11B1 | |
| SCHEMBL15419777 | 0.84 | HSD11B1 (0.83) | HSD11B1KCNH2 | |
| SCHEMBL15419902 | 0.83 | HSD11B1 (0.84) | HSD11B1KCNH2 | |
| SCHEMBL15419994 | 0.83 | HSD11B1 (0.84) | HSD11B1KCNH2 | |
| SCHEMBL15419992 | 0.83 | HSD11B1 (0.67) | HSD11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073906-B2 | Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-07-07 | — | — | US | claimed |
| EP-2740723-A2 | SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Korea Research Institute of Chemical Technology (KR) | 2014-06-11 | — | — | EP | claimed |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-01-23 | — | — | US | claimed |
| US-20240108632-A1 | PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION AS OPHTHALMIC DROP TO PATIENT REQUIRING OPTIC NERVE PROTECTION | PINOTBIO, INC. (KR) | 2024-04-04 | — | — | US | disclosed |
| EP-2740723-B1 | SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2017-05-10 | — | — | EP | disclosed |
| US-9073906-B2 | Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-07-07 | — | — | US | disclosed |
| EP-2740723-A2 | SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Korea Research Institute of Chemical Technology (KR) | 2014-06-11 | — | — | EP | disclosed |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885HSD11B2 2/4885KCNH2 4365/4885 |
| US-20240108632-A1 | PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION AS OPHTHALMIC DROP TO PATIENT REQUIRING OPTIC NERVE PROTECTION | PMP22, PDE6C, DSC1 | HSD11B1 154/4885HSD11B2 303/4885KCNH2 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.